Get started
Author

Yotsawaj Runglodvatana

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
2024 · Shun Lu, Terufumi Kato, et al. · New England Journal of Medicine · 370
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · Bruno Sangro, Masatoshi Kudo, et al. · The Lancet · 339
PDF
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
2023 · M. Burotto, Z. Zvirbule, et al. · Annals of Oncology · 62
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
2026 · R. Dent, Z. Shao, et al. · Annals of Oncology · 48
OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
2023 · J. He, S. Gao, et al. · Journal of Thoracic Oncology · 21
PDF
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
2025 · David Planchard, Hye Ryun Kim, et al. · Journal of Thoracic Oncology · 13
PDF
OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
2024 · D. Planchard, H.R. Kim, et al. · Journal of Thoracic Oncology · 13
PDF
1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
2023 · D. Planchard, J.R. Brahmer, et al. · Annals of Oncology · 8
PDF
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
2025 · Solange Peters, Stephen V. Liu, et al. · Journal of Clinical Oncology · 7
PDF
Effect of a Peaceful End-of-Life Care Program on Perceived Good Death in People With Advanced Cancer and Their Family Caregivers
2025 · Benchamart Trakoolngamden, Supreeda Monkong, et al. · Journal of Hospice and Palliative Nursing · 6
1461 Phase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1
2024 · Jarushka Naidoo, Solange Peters, et al. · Journal for ImmunoTherapy of Cancer · 5
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
2023 · Christos Chouaid, Gwo Fuang Ho, et al. · Journal of Clinical Oncology · 3
PDF
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
2026 · Masatoshi Kudo, Ghassan K Abou-Alfa, et al. · The Lancet Oncology · 2
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1
2026 · Jarushka Naidoo, Solange Peters, et al. · Lung Cancer · 2
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
2024 · M. Burotto, Z. Zvirbule, et al. · Annals of Oncology · 2
61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
2022 · M. Burotto, Z. Zvirbule, et al. · Immuno-Oncology Technology · 2
PDF
PL03.04: Zipalertinib Plus Chemotherapy for 1st Line NSCLC with EGFR Exon 20 Insertions: Results From the Phase 3 Trial (REZILIENT 3)
2026 · D.S. Tan, P. Danchaivijitr, et al. · Journal of Thoracic Oncology
PP01.58: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) in Combination with Chemotherapy in First-Line (1L) Non-Small Cell Lung Cancer (NSCLC) – ROSETTA Lung-02
2026 · Solange Peters, Stephen V. Liu, et al. · Journal of Thoracic Oncology
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
2026 · Shun Lu, Terufumi Kato, et al. · Future Oncology
PDF
1854P IMscin001 final analysis: A randomised phase III study of subcutaneous (SC) versus intravenous (IV) atezolizumab (atezo) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
2025 · M. Burotto, Z. Zvirbule, et al. · Annals of Oncology
Works count: 20
Citation count: 895
H-index: 8
I10-index: 7
Year
Topic
Type